ABSTRACT
El dengue es en la actualidad la enfermedad viral más relevante de transmisión vectorial hiperendémica en las Américas. El incremento en el número de casos se ha relacionado con la aparición de dengue durante la gestación y en el periodo neonatal. De acuerdo con la edad de gestación en la que ocurra la infección, podrían presentarse manifestaciones en el feto, como aborto, y en los pacientes a término, dengue neonatal. En este artículo se presenta una reseña de los casos reportados a nivel mundial, y especialmente en las Américas, así como aspectos fisiopatogénicos de la enfermedad.
Dengue is currently the most important viral disease transmitted by arthropods and which is hyperendemic in the Americas. An increase in the number of cases is related to dengue during pregnancy and the neonatal period. According to the gestational age in which infection occurs, there could be different manifestations in the fetus including abortion, malformations or neonatal dengue in newborns. This article presents a review regarding some cases reported worldwide, especially in the Americas, and some pathophysiologic issues related to perinatal dengue.
Subject(s)
Infant, Newborn , Dengue , HELLP Syndrome , Severe DengueABSTRACT
Dengue is currently the most important viral disease transmitted by arthropods and which is hyperendemic in the Americas. An increase in the number of cases is related to dengue during pregnancy and the neonatal period. According to the gestational age in which infection occurs, there could be different manifestations in the fetus including abortion, malformations or neonatal dengue in newborns. This article presents a review regarding some cases reported worldwide, especially in the Americas, and some pathophysiologic issues related to perinatal dengue.
Subject(s)
Dengue/epidemiology , Fetal Diseases/epidemiology , Infectious Disease Transmission, Vertical , Abnormalities, Multiple/etiology , Abortion, Spontaneous/etiology , Adolescent , Age of Onset , Dengue/congenital , Dengue/embryology , Dengue/physiopathology , Diagnostic Errors , Female , Fetal Diseases/virology , Gestational Age , HELLP Syndrome/diagnosis , Humans , Infant, Newborn , Jaundice, Neonatal/etiology , Male , Pregnancy , Pregnancy Complications, Infectious/virology , Puerperal Disorders/diagnosis , Risk Factors , Sepsis/diagnosisABSTRACT
The current treatment for dengue hemorrhagic fever largely consists of supportive care. The drug pentoxifylline has been shown to blunt the proinflammatory actions of tumor necrosis factor-α, a key mediator of dengue hemorrhagic fever. We performed a pilot study evaluating pentoxifylline's effect on 55 children with dengue hemorrhagic fever. We believe our findings support the existing literature on its potential use in severe infection.
